Академический Документы
Профессиональный Документы
Культура Документы
DOI 10.1007/s10156-011-0298-y
ORIGINAL ARTICLE
Received: 16 March 2011 / Accepted: 16 August 2011 / Published online: 9 September 2011
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2011
Abstract Surgical-site infection (SSI) is a major contributor to patient mortality rates and health care costs. Due to the
high risk of bacterial contamination, colorectal surgery is
associated with a particularly high risk of postoperative
infection. The surveillance reported here was conducted at
Aichi Medical University Hospital on 304 patients who
underwent elective colorectal resectiontotal or partial
from June 2006 to May 2009. To determine risk factors for
SSI, multivariate analysis was used. Forty-six (15.1%)
patients were diagnosed with SSI. Patients who received
cefotiam for prophylaxis showed the highest incidence of SSI
(26.6%), and patients who were administered omoxef
showed the lowest incidence (8.1%). Patients who developed
SSI were more likely to intraoperative blood loss
(308.1 29.8 vs. 153.9 12.2; p \ 0.05), longer postoperative antimicrobial administration (5.3 2.2 vs. 4.5 1.5;
p \ 0.05), and longer operative time (3.3 1.6 vs.
2.7 1.2; p \ 0.05). Intraoperative bleeding, antimicrobial
choices to cover both anaerobic and aerobic bacteria, and
length of antimicrobial administration were independently
predictive of SSI development according to multivariate
logistic regression analysis. These results suggest that the
degree of operative invasion and anaerobic bacteria contribute to SSI following colorectal surgery.
Introduction
Surgical-site infection (SSI) is dened as infections
occurring within 30 daysor within 1 year in the case of
implantation of a foreign bodyafter surgery and
affecting either the incision (supercially or deeply),
organs, or body spaces at the site of operation [1]. In
2002, the US Centers for Medicare and Medicaid Services
implemented the National Surgical Infection Prevention
Project. This project builds on experience that the US
Centers for Disease Control and Prevention (CDC) have
gained from implementing the National Nosocomial
Infections Surveillance System (CDC-NNIS). According
to data from the system, SSI accounts for 1416% of
reported nosocomial infections among all hospitalized
patients and 38% among surgical patients [1, 2]. In Europe,
available data show that the incidence of SSI can be as high
as 20% depending on surgical procedure, surveillance
criteria, and study design.
As for patient resistance, intrinsic patient characteristics
strictly correlating with an increased risk of SSI include
advanced age, an American Society of Anesthesiologists
(ASA) score of III, obesity, pre-existing illness, and hostdefense deciency [38]. Moreover, risk factors for SSI
related to the surgical procedure include quality of surgical
care, diabetes mellitus, surgery type and duration, emergency procedure, blood transfusion, intraoperative hypothermia, and systemic hypoxemia [912]. Additionally, SSI
is a major contributor to patient mortality rates and health
care costs. Mortality rates were two to three times higher in
patients in whom SSI developed compared with uninfected
123
84
123
85
304 (209/95)
Age (year)
66 12
(19 to 91)
Sex (male/female)
181/123
51/253
2.8 1.3
(0.41 to 8.52)
191.8 252.1
(3.0 to 920.0)
36.4 2.8
(35.8 to 38.9)
37.1 0.6
(35.1 to 40.0)
125.9 29.3
(119.5 to 192.0)
138.9 35.8
(74.8 to 258.0)
158.9 36.6
(151.1 to 231.0)
ASA score
1
73 (24.0%)
194 (63.8%)
26 (8.6%)
1 (0.3%)
Antimicrobial prophylaxis
(yes/no) (case)
302/2
Cefmetazole
36 (11.9%)
Cefotiam
64 (21.2%)
Flomoxef
136 (45.0%)
Piperacillin
51 (16.9%)
Other
15 (5.0%)
5/46 (9.8%)
Cefotiam
17/47 (26.6%)
Flomoxef
11/125 (8.1%)
Piperacillin
5/31 (13.9%)
14.9 17.1
(-109.0 to 86.0)
4.6 1.7
(1.0 to 14.0)
42 (13.8%)
41/263
Discussion
Antimicrobial prophylaxis to prevent SSI is one of the most
widely accepted practices in surgery. Our results showed
that 99.4% of all patients who received elective colorectal
surgery were administered antimicrobial prophylaxis. SSI
incidence in for colorectal resections during the study
period was 15.1%, which was in range with a general
review of the literature [26, 30, 31].
123
86
Table 2 Comparison between surgical-site infection (SSI) group and non-SSI group
SSI
Non-SSI
28/18
181/77
Age (year)
66.9 1.8
66.0 0.7
NS
Sex (male/female)
27/19
154/104
NS
6/40
44/214
NS
3.3 1.6
2.7 1.2
\0.05
308.1 29.8
153.9 12.2
\0.05
37.3 0.7
36.9 2.4
NS
37.1 0.8
36.0 5.1
NS
124.3 7.09
126.0 10.1
NS
136.8 37.5
139.3 35.6
NS
175.5 40.3
1.84 0.08
158.2 36.7
1.84 0.03
NS
NS
16.7 2.5
14.8 1.0
NS
24.0 8.2
12.7 2.5
NS
NS
Cefotiam
18.9 3.9
19.3 2.1
NS
Flomoxef
10.3 4.3
15.2 1.4
NS
25.4 5.2
12.2 2.1
\0.05
5.3 2.2
4.5 1.5
\0.05
7/39
35/223
NS
3/43
38/220
NS
Piperacillin
Pearsons v test for categorical variables or Fisher exact test, which was used when the variables were \5, was used to analyze categorized
variables. The t test was used to analyze continuous variables
2
123
87
Table 3 Comparison of surgical-site infection (SSI) risk factors in each antimicrobial group
Cefmetazole
Cefotiam
Flomoxef
Piperacillin
26/10
39/25
98/38
33/18
Age (year)
65.0 12.33
68.21 10.13
64.86 11.08
66.25 12.78
20/16
37/27
82/54
33/18
Sex (male/female)
Diabetic mellitus (yes/no)
5/31
10/54
29/107
3/48
2.6 1.2
2.8 1.3
3.0 1.3
3.2 1.6
180.0 33.7
168.1 25.1
161.7 17.2
209.5 27.9
37.3 0.4
37.1 0.3
36.7 0.2
37.1 0.3
34.9 0.8
36.9 0.6
35.9 0.4
36.8 0.7
121.8 15.4
125.5 32.9
127.7 27.5
116.6 37.5
136.5 32.6
142.0 33.6
138.5 32.0
136.0 37.4
179.5 37.0
168.5 40.5
155.5 35.6
148.0 1.73
ASA score
1.83 0.59
1.87 0.46
1.78 0.68
1.85 0.61
13.6 2.6
19.1 2.0
14.4 1.3
4.4 2.2
4.8 1.6
4.4 1.6
5.0 1.6
4.1 1.4
5/31
10/54
12/124
16/35
5/31
12/52
11/125
10/41
Odds ratio
95% CI
P value
0.06
0.020.22
\0.05
0.06
0.0040.76
\0.05
Cefotiam
0.32
0.150.70
\0.05
Stepwise method (step-forward). Coefcients: number of operations (colon/rectal), age, sex, diabetes mellitus (yes/no), operation time (h), blood
loss (ml), intraoperative body temperature (C), postoperative body temperature (C), blood sugar level (mg/dl) (day 0), blood sugar level (mg/dl)
(day 1), blood sugar level (mg/dl) (day 2), American society of Anesthesiologists score, antimicrobial prophylaxis (cefmetazole, cefotium,
omoxef, piperacillin), term of postoperative administration of antimicrobial agents, intraoperative redosing (case), laparoscopic surgery (yes/no)
CI condence interval
criticized as being unsuitable for risk evaluation in colorectal surgery because most patients undergoing such the
procedure have an ASA score of 1 or 2 and a wound
classication of cleancontaminated.
There are several important limitations to this study.
First, this was retrospective analysis and not a randomized
controlled study to examine the signicance of specic risk
factors for SSI. Therefore, there was some variability
among practices [the use of antimicrobial-coated sutures,
mechanical bowel preparation (glycolelectrolyte solution
or 2-Hydroxy-1,2,3-propanetricarboxylic acid magnesium
salt)]. Second, we did not take into account stratication by
surgeon because this study was conducted in a hospital.
Although the term of investigation was 3 years, a few
surgeons in a group conducted colorectal surgeries. Additionally, SSI is categorized into incisional and organ/space
123
88
123
References
1. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR.
Guideline for prevention of surgical site infection, 1999. Hospital
Infection Control Practices Advisory Committee. Infect Control
Hosp Epidemiol. 1999;20:25078.
2. Emori TG, Gaynes RP. An overview of nosocomial infections,
including the role of the microbiology laboratory. Clin Microbiol
Rev. 1993;6:42842.
3. Smith RL, Bohl JK, McElearney ST, Friel CM, Barclay MM,
Sawyer RG, et al. Wound infection after elective colorectal
resection. Ann Surg. 2004;239:599605.
4. Kaye KS, Schmit K, Pieper C, Sloane R, Caughlan KF, Sexton
DJ, et al. The effect of increasing age on the risk of surgical site
infection. J Infect Dis. 2005;191:105662.
5. Garibaldi RA, Cushing D, Lerer T. Risk factors for postoperative
infection. Am J Med. 1991;91:158S63S.
6. Woodeld JC, Beshay NM, Pettigrew RA, Plank LD, van Rij
AM. American Society of Anesthesiologists classication of
physical status as a predictor of wound infection. ANZ J Surg.
2007;77:73841.
7. Choban PS, Heckler R, Burge JC, Flancbaum L. Increased incidence of nosocomial infections in obese surgical patients. Am
Surg. 1995;61:10015.
8. Haley RW, Culver DH, Morgan WM, White JW, Emori TG,
Hooton TM. Identifying patients at high risk of surgical wound
infection. A simple multivariate index of patient susceptibility
and wound contamination. Am J Epidemiol. 1985;121:20615.
9. Allen DB, Maguire JJ, Mahdavian M, Wicke C, Marcocci L,
Scheuenstuhl H, et al. Wound hypoxia and acidosis limit neutrophil bacterial killing mechanisms. Arch Surg. 1997;132:9916.
10. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to
reduce the incidence of surgical-wound infection and shorten
hospitalization. Study of Wound Infection and Temperature
Group. N Engl J Med. 1996;334:120915.
11. Gottrup F, Firmin R, Rabkin J, Halliday BJ, Hunt TK. Directly
measured tissue oxygen tension and arterial oxygen tension
assess tissue perfusion. Crit Care Med. 1987;15:10306.
12. Hopf HW, Hunt TK, West JM, Blomquist P, Goodson WH 3rd,
Jensen JA, et al. Wound tissue oxygen tension predicts the risk of
wound infection in surgical patients. Arch Surg. 1997;132:
9971004.
13. Astagneau P, Rioux C, Golliot F, Brucker G, INCISO Network
Study Group. Morbidity and mortality associated with surgical
site infections: results from the 19971999 INCISO surveillance.
J Hosp Infect. 2001;48:26774.
14. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein
MZ, Trivette SL, et al. Adverse clinical and economic outcomes
attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis.
2003;36:5928.
15. Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ.
The impact of surgical-site infections in the 1990s: attributable
mortality, excess length of hospitalization, and extra costs. Infect
Control Hosp Epidemiol. 1999;20:72530.
16. Sutter VL. Frequency of occurrence and antimicrobial susceptibility of bacterial isolates from the intestinal and female genital
tracts. Rev Infect Dis. 1983;5:S849.
17. Baum ML, Anish DS, Chalmers TC, Sacks HS, Smith H Jr,
Fagerstrom RM. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med. 1981;305:7959.
18. Silver A, Eichorn A, Kral J, Pickett G, Barie P, Pryor V, et al.
Timeliness and use of antibiotic prophylaxis in selected inpatient
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
89
29.
30.
31.
32.
33.
34.
35.
36.
37.
123